Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III (ACCROS-III)

Inclusion Criteria: Male or female patients between 18 and 65 years (both inclusive) Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected or proof of positive test ≤3 days before randomization) Patients with mild COVID-19 have the following symptoms and signs prior to randomization (≤ 3days) Upper respiratory tract symptoms (&/or fever) without shortness of breath or hypoxia. (SpO2 > 94 %) Willingness to sign written informed consent document Exclusion Criteria: < 18 years of age Hospitalized patients Subject with known allergy or hypersensitivity to the components of the formulation. Patients receiving therapy with Monoamine oxidase inhibitors (MAOIs): rasagline, selegiline, isocarbonboxasid, phenelzine, tranylcypromine. Patients with narrow-angle glaucoma urinary retention Sleep Apnea History of immunodeficiency or receiving immunosuppressive therapy. Patients with acute exacerbation of severe comorbidities such as chronic obstructive pulmonary disease (COPD), class 3 and 4 heart failure diagnosed according to the criteria of the New York Heart Failure Association (NYHA), or diseases with severe oxygenation problems Any Surgical procedure in the past 12 weeks Unable to make informed consent or refuse or renounce adherence to standard treatment protocols. Any significant illness or drugs that could interfere with study parameters Any other condition based on the investigator's clinical judgment does not justify the patient's participation in the study. Participation in another clinical trial within the past 30 days Clinically significant arrhythmia or symptomatic cardiac conditions including but not limited to QT elongation QT interval less than 300 ms or more than 500 ms for both men and women.